Nautilus Biotechnology In... (NAUT)
NASDAQ: NAUT
· Real-Time Price · USD
0.82
-0.05 (-5.30%)
At close: May 16, 2025, 3:59 PM
0.80
-2.90%
After-hours: May 16, 2025, 04:54 PM EDT
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
The company was founded in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology Inc.
| Country | United States |
| IPO Date | Aug 7, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 134 |
| CEO | Sujal M. Patel |
Contact Details
Address: 2701 Eastlake Avenue East Seattle, Washington United States | |
| Website | https://www.nautilus.bio |
Stock Details
| Ticker Symbol | NAUT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001808805 |
| CUSIP Number | 63909J108 |
| ISIN Number | US63909J1088 |
| Employer ID | 00-0000000 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Sujal M. Patel | Co-Founder, Chief Executive Officer, President, Secretary & Director |
| Anna Mowry | Chief Financial Officer & Treasurer |
| Kentaro Suzuki | Chief Marketing Officer |
| Dr. Parag Mallick Ph.D. | Co-Founder, Chief Scientist & Director |
| Matthew B. Murphy ESQ. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 4 | Filing |
| May 02, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 29, 2025 | 10-Q | Quarterly Report |
| Apr 29, 2025 | 8-K | Current Report |
| Mar 21, 2025 | 4 | Filing |
| Mar 05, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 05, 2025 | SCHEDULE 13D/A | [Amend] Filing |